Saturday, August 29, 2015

Tuesday Features

Peritech readies U.S. launch of novel hemorrhoid gel

Peritech readies U.S. launch of novel hemorrhoid gel

Closely-held Peritech Pharma of Israel is in discussions with potential marketing partners for a U.S. launch of its once-daily over-the-counter gel, now known as PP-110, for the treatment of hemorrhoids. Raveh Gill-More “PP-110 contains the same active pharmaceutical ingredients as Pfizer’s Preparation-H cream: pramoxine-HCI 1% and phenylephrine-HCI... [Read more of this feature]


Cellectar Biosciences refocusing on therapeutics

Cellectar Biosciences refocusing on therapeutics

After completing a strategic review of its cancer therapeutic and cancer diagnostic assets, Cellectar Biosciences (NASDAQ:CLRB) has refocused the company on its phospholipid ether drug conjugate (PDC) platform and cancer-targeting delivery of oncologic payloads. Jim Caruso “We were previously focused on advancing our diagnostic assets, with no plan... [Read more of this feature]


BriaCell readies trial of breast cancer vaccine

BriaCell readies trial of breast cancer vaccine

BriaCell Therapeutics (OTCQX:ANCCF; TSX-V:BCT) anticipates enrolling the first patient later this year in a Phase 1/2 open label study of its BriaVax vaccine in up to 24 breast cancer patients with advanced stages of solid tumors. Dr. Joseph Wagner “While the current focus of the company remains late-staged breast cancers, we recognized that the technology... [Read more of this feature]


More Posts From Tuesday Features

Briefs

Cantor starts Affymetrix at buy

Cantor starts Affymetrix at buy

Cantor Fitzgerald has initiated coverage of Affymetrix (NASDAQ:AFFX) with a “buy’ rating and $13 target price. The stock closed at $8.83 on Wednesday. “Over the last four years, management has retooled its product portfolio, reorganized the business units, diversified away from gene expression, and returned the company to profitability,” writes... [Read more of this brief]


Leerink starts Teladoc at outperform

Leerink starts Teladoc at outperform

Leerink Partners has launched coverage of Teladoc (NYSE:TDOC) with an “outperform” rating and $35 price target. The stock closed at $25.28 on Wednesday. “Powerful megatrends such as healthcare cost inflation, provider shortages, and healthcare consumerism have converged to draw telehealth into the mainstream, and Teladoc is well positioned to... [Read more of this brief]


Cantor starts Pacific Biosciences at buy

Cantor starts Pacific Biosciences at buy

Cantor Fitzgerald has initiated coverage of Pacific Biosciences of California (NASDAQ:PACB) with a “buy” rating and a 12-month target price of $9. The stock closed at $4.58 on Wednesday. Pacific is a pure-play sequencing company with an estimated 2% share of the $2.3-billion sequencing market. “In each of the last two years, Pacific has improved... [Read more of this brief]


Knight to commercialize Advaxis drugs in Canada

Knight to commercialize Advaxis drugs in Canada

Advaxis (NASDAQ:ADXS) has entered into a licensing agreement with Knight Therapeutics (TSX:GUD) to commercialize in Canada Advaxis’ product portfolio, including its three lead drug candidates: axalimogene filolisbac (ADXS-HPV) for human papilloma virus-associated cancers, ADXS-PSA for prostate cancer and ADXS-HER2 for HER2 expressing solid tumors. In... [Read more of this brief]


Roth ups Sarepta Therapeutics price target to $50

Roth ups Sarepta Therapeutics price target to $50

Roth Capital Partners has raised its price target for Sarepta Therapeutics (NASDAQ:SRPT) to $50 from $45 after the FDA set Feb 26 as the PDUFA date to consider approval of the company’s NDA for eteplirsen. The stock closed at $32.58 on Tuesday. Eteplirsen is indicated for the treatment of Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping.... [Read more of this brief]


More Posts From Briefs
Email Newsletters with Constant Contact
Google+